Clinical trials: Streptococcus Pneumoniae Infections
Pneumococcal Disease
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07573462
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 78 sites in United States, Argentina and 8 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Pfizer
PNAG-expressing Pathogenic Microbes Vaccine
A Study of AV0328 Administered to Healthy Adult Volunteers
AV0328 is a novel vaccine candidate intended to raise antibodies to the glucosamine backbone of naturally occurring Poly N-acetyl glucosamine (PNAG), a capsular polysaccharide expressed on the surface of a wide array of microbes.
- Trial name
- NCT02853617
- Testing
- AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Alopexx Vaccine, LLC
Pneumococcal Diseases
Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey
The aim of this study is to specify the serotype distribution of Streptococcus pneumoniae that causes invasive diseases at children and adults in Turkey.
- Trial name
- NCT01810861
- Testing
- There is no intervention in this study
- Where
- 32 sites in Turkey (Türkiye)
- Volunteers
- 922 people
- Sponsor
- Pfizer
Hepatitis B, Acellular Pertussis
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
The purpose of this study is to assess the safety in terms of fever (rectal temperature) higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal…
- Conditions
- Hepatitis B, Acellular Pertussis, Tetanus, Poliomyelitis
- Trial name
- NCT00463437
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Infanrix hexa
- Where
- 63 sites in Germany, Poland and 1 more
- Volunteers
- 1,437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
This study is a combination of a Phase I and Phase III study design. The Phase I portion is an open-label, controlled study to evaluate the safety of 7vPnC in healthy Chinese infants.
- Trial name
- NCT00488826
- Testing
- 7-valent pneumococcal conjugate vaccine, Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diphtheria, Tetanus
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers
The purpose of this study is to evaluate safety and immunogenicity of Pediacel® in infants and toddlers when given at 2,3,4 and 12-18 months of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT00343421
- Testing
- PEDIACEL® and Prevenar®, Infanrix®-IPV+Hib and Prevenar®
- Where
- 2 sites in France, Poland
- Volunteers
- 588 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Invasive Pneumococcal Disease
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.
- Trial name
- NCT01128439
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Measles, Mumps
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00109343
- Testing
- Comparator: ProQuad™ (V221), Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
- Volunteers
- 1,027 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Meningococcal, Meningococcal Vaccines
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines
The purpose of this study is to evaluate immunogenicity and safety of meningococcal conjugate vaccine GSK134612 compared to the licensed vaccines MenC-CRM197 and MenC-TT in infants of 2 months of age.
- Trial name
- NCT01144663
- Testing
- Nimenrix™, Menjugate®, NeisVac-CTM
- Where
- 44 sites in Estonia, Germany and 1 more
- Volunteers
- 2,095 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan
Streptococcus pneumoniae is a major cause of pneumonia, among infants and children in Japan and worldwideThis study plans to investigate the rate of invasive pneumococcal disease "IPD " and the rate of hospitalizations due to…
- Trial name
- NCT00757575
- Where
- 2 sites in Japan
- Volunteers
- 28,511 people
- Sponsor
- Pfizer
Meningococcal Meningitis, Measles
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00483574
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV)
- Where
- 79 sites in United States, Chile
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in…
- Trial name
- NCT06524414
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
- Where
- 67 sites in United States, Puerto Rico
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease.
- Trial name
- NCT06182124
- Testing
- Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 20 sites in United States
- Volunteers
- 1,710 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
- Trial name
- NCT04382326
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 1,997 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults at increased risk for pneumococcal disease and to 2) describe the safety…
- Trial name
- NCT03547167
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 1,515 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Diseases
A Study to Evaluate 20vPnC in Healthy Chinese Infants
The purpose of this study is to evaluate a study vaccine called 20-valent pneumococcal conjugate vaccine (20vPnC). The study will assess whether the study vaccine is safe to use in healthy infants.
- Trial name
- NCT07754539
- Testing
- 20vPnC, 13vPnC
- Where
- 4 sites in China
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Pfizer
Community-Acquired Pneumonia (CAP)
A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
The purpose of this study is to learn how well PCV20 stops adults from getting community-acquired pneumonia. Pneumonia is an infection of the lungs that can be caused by germs like bacteria, virus, or fungi.
- Trial name
- NCT07251465
- Testing
- Receipt of PCV20
- Where
- United States
- Volunteers
- 846,279 people
- Sponsor
- Pfizer
Infections, Streptococcal
Booster and Catch-up Vaccination With Vaccine GSK1024850A
The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of pneumococcal vaccine GSK1024850A administered either at 9-18 months or 15-18 months of age in children primed in primary…
- Trial name
- NCT01030822
- Testing
- Pneumococcal vaccine GSK1024850A
- Where
- 4 sites in India
- Volunteers
- 282 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza and Pneumonia
Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine
This study is an open-label,single center phase Ⅳ clinical trial of combined immunization with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine.The purpose of this study is to evaluate the safety…
- Trial name
- NCT05471531
- Testing
- Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine, Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine
- Where
- 4 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants Aged 2-23 Months
A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.
- Trial name
- NCT06800261
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.